MALVERN, PA and EXETER, NH--(Marketwire - January 22, 2008) - Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) and Bentley Pharmaceuticals, Inc. (NYSE: BNT) today announced that the United States Patent and Trademark Office (“USPTO”) has issued U.S. Patent No. 7,320,968 covering Testim®, 1% testosterone gel, marketed by Auxilium under license from Bentley. The patent will expire in January 2025. Auxilium plans to list the patent promptly in Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book), published by the U.S. Food and Drug Administration. The companies also announced that Bentley has filed a divisional application and continuations with the USPTO, which, if granted, may expand the scope of patent claims covering Testim.
